Figure 1:.
SDS-PAGE analyses of polyhedra (A) and ODVs (B) of AcAaIT (lanes 1), AcAaIT-laboratory (lanes 2), AcAaIT-field (lanes 3), AcMNPV (lanes 4), and SlNPV (lanes 5). The molecular weight of size standards (lanes M) are indicated to the left.
Figure 1:.
SDS-PAGE analyses of polyhedra (A) and ODVs (B) of AcAaIT (lanes 1), AcAaIT-laboratory (lanes 2), AcAaIT-field (lanes 3), AcMNPV (lanes 4), and SlNPV (lanes 5). The molecular weight of size standards (lanes M) are indicated to the left.
Figure 2:.
Two-dimentional titration of various dilutions of serum against AcAaIT polyhedrin with different concentrations (0.0, 1.25, 2.5, 5, 10 and 20 μg/ml) of AcAaIT polyhedrin as the coating antigen.
Figure 2:.
Two-dimentional titration of various dilutions of serum against AcAaIT polyhedrin with different concentrations (0.0, 1.25, 2.5, 5, 10 and 20 μg/ml) of AcAaIT polyhedrin as the coating antigen.
Figure 3:.
ELISA inhibition curves for 4 analytes: polyhedrin from AcAaIT (A), AcAaIT-field (B), AcMNPV (C), and SlNPV (D). Reagent concentrations: antiserum 1:4,000 (final dilution in wells); AcAaIT polyhedrin (2.5 μg/ml) was used as the coating antigen.
Figure 3:.
ELISA inhibition curves for 4 analytes: polyhedrin from AcAaIT (A), AcAaIT-field (B), AcMNPV (C), and SlNPV (D). Reagent concentrations: antiserum 1:4,000 (final dilution in wells); AcAaIT polyhedrin (2.5 μg/ml) was used as the coating antigen.
Figure 4:.
Restriction endonuclease profiles of DNAs isolated from AcAaIT (lanes 1), AcAaIT-laboratory (lanes 2), or AcAaIT-field (lanes 3) following treatment with HindIII or BamHI and electrophoresis in a 0.8% agarose gel. The sizes of molecular weight standards of lambda phage DNA digested with HindIII (lanes M) are indicated to the left.
Figure 4:.
Restriction endonuclease profiles of DNAs isolated from AcAaIT (lanes 1), AcAaIT-laboratory (lanes 2), or AcAaIT-field (lanes 3) following treatment with HindIII or BamHI and electrophoresis in a 0.8% agarose gel. The sizes of molecular weight standards of lambda phage DNA digested with HindIII (lanes M) are indicated to the left.
Figure 5:.
SDS-PAGE of serum proteins from rats at 21 days post oral treatment (panel 1) or intraperitoneal injection (panel 2) of baculovirus: control males (lanes b and k), control females (lanes c and l), SlNPV exposed males (lanes d and m), SlNPV exposed females (lanes e and n), AcMNPV exposed males (lanes f and o), AcMMPV exposed females (lanes g and p), AcAaIT exposed males (lanes h and q), AcAaIT exposed females (lanes i and r). The sizes of molecular weight standards (lanes a and j) are indicated to the left of panel 1.
Figure 5:.
SDS-PAGE of serum proteins from rats at 21 days post oral treatment (panel 1) or intraperitoneal injection (panel 2) of baculovirus: control males (lanes b and k), control females (lanes c and l), SlNPV exposed males (lanes d and m), SlNPV exposed females (lanes e and n), AcMNPV exposed males (lanes f and o), AcMMPV exposed females (lanes g and p), AcAaIT exposed males (lanes h and q), AcAaIT exposed females (lanes i and r). The sizes of molecular weight standards (lanes a and j) are indicated to the left of panel 1.
Figure 6:.
Histopathology of liver from female rats treated with saline (a) showing normal hepatic parenchyma; AcAaIT (b) showing mild reversible degenerative changes (MDC) in a few hepatocytes; AcMNPV (c) showing mild leukocyte aggregation (MLA) in the portal area; and SlNPV (d) showing vascular and hydropic degeneration (D) of some hepatocytes (H&E ×300).
Figure 6:.
Histopathology of liver from female rats treated with saline (a) showing normal hepatic parenchyma; AcAaIT (b) showing mild reversible degenerative changes (MDC) in a few hepatocytes; AcMNPV (c) showing mild leukocyte aggregation (MLA) in the portal area; and SlNPV (d) showing vascular and hydropic degeneration (D) of some hepatocytes (H&E ×300).
Figure 7:.
Histopathology of kidney from female rats treated with saline (a) showing normal renal tissue structures; AcAaIT (b) showing mild dilation and hyperemia (MDH) of glomerular capillaries; AcMNPV (c) showing congested (C) renal blood vessels and hypercellularly (H) of some glomeruli; and SlNPV (d) showing congested glomeruli and interregnal capillaries (CGIC) (H&E ×300).
Figure 7:.
Histopathology of kidney from female rats treated with saline (a) showing normal renal tissue structures; AcAaIT (b) showing mild dilation and hyperemia (MDH) of glomerular capillaries; AcMNPV (c) showing congested (C) renal blood vessels and hypercellularly (H) of some glomeruli; and SlNPV (d) showing congested glomeruli and interregnal capillaries (CGIC) (H&E ×300).
Figure 8:.
Histopathology of intestine from female rats treated with saline (a) showing showing apparently normal intestinal mucosa; AcAaIT (b) showing metaplasia (M) to goblet cells in the villus epithelium; AcMNPV (c) showing mucinous degeneration (MD); and SlNPV (d) showing mild mucus and metaplasia (M) of intestinal epithelium to global cells (H&E ×300).
Figure 8:.
Histopathology of intestine from female rats treated with saline (a) showing showing apparently normal intestinal mucosa; AcAaIT (b) showing metaplasia (M) to goblet cells in the villus epithelium; AcMNPV (c) showing mucinous degeneration (MD); and SlNPV (d) showing mild mucus and metaplasia (M) of intestinal epithelium to global cells (H&E ×300).
Figure 9:.
Histopathology of stomach from female rats treated with saline (a) showing normal gastric mucosa; AcAaIT (b) showing leukocytic infiltration (LI) in mucosa and submucosa; AcMNPV (c) showing lymphocytic aggregation (LA) in gastric mucosa; and SlNPV (d) showing edema and leukocytic infiltration (ELI) in gastric submucosa (H&E s300).
Figure 9:.
Histopathology of stomach from female rats treated with saline (a) showing normal gastric mucosa; AcAaIT (b) showing leukocytic infiltration (LI) in mucosa and submucosa; AcMNPV (c) showing lymphocytic aggregation (LA) in gastric mucosa; and SlNPV (d) showing edema and leukocytic infiltration (ELI) in gastric submucosa (H&E s300).
Figure 10:.
Histopathology of lung from female rats treated with saline (a) showing normal pulmonary tissue; AcAaIT (b) showing mild thickening (T) of some interaveolar septa; AcMNPV (c) showing vaculated bronchialar epithelium (VBE) and peribronchial lymphoid hyperplasia (PLH); and SlNPV (d) showing perivascular lymphoid aggregates (PLA) (H&E ×300).
Figure 10:.
Histopathology of lung from female rats treated with saline (a) showing normal pulmonary tissue; AcAaIT (b) showing mild thickening (T) of some interaveolar septa; AcMNPV (c) showing vaculated bronchialar epithelium (VBE) and peribronchial lymphoid hyperplasia (PLH); and SlNPV (d) showing perivascular lymphoid aggregates (PLA) (H&E ×300).
Figure 11:.
Histopathology of spleen from female rats treated with saline (a) showing normal splenic tissue; AcAaIT (b) showing scattered hemosidrin pigment (SHP) in the splenic red pulps; AcMNPV (c) showing mild hyperplasia of white pulps and hemosidrosis (HH); and SlNPV (d) showing mild lymphoid depletion (LD) (H&E ×300).
Figure 11:.
Histopathology of spleen from female rats treated with saline (a) showing normal splenic tissue; AcAaIT (b) showing scattered hemosidrin pigment (SHP) in the splenic red pulps; AcMNPV (c) showing mild hyperplasia of white pulps and hemosidrosis (HH); and SlNPV (d) showing mild lymphoid depletion (LD) (H&E ×300).
Figure 12:.
Histopathology of brain from female rats treated with saline (a) showing normal brain tissue; AcAait (b) showing scatterd glial cells (SGC) within the brain tissue; AcMNPV (c) showing aggregation of glial cells (AGC) between nerve fibers; and SlNPV (d) showing proliferation of glial cells (PGC) in the cerebral cortex (H&E ×300).
Figure 12:.
Histopathology of brain from female rats treated with saline (a) showing normal brain tissue; AcAait (b) showing scatterd glial cells (SGC) within the brain tissue; AcMNPV (c) showing aggregation of glial cells (AGC) between nerve fibers; and SlNPV (d) showing proliferation of glial cells (PGC) in the cerebral cortex (H&E ×300).
Table 1:.
Absorbance at 450 nm using different concentrations of antigen and different dilutions of serum antibody.
Table 1:.
Absorbance at 450 nm using different concentrations of antigen and different dilutions of serum antibody.
Antibody dilutions | Antigen concentrations* |
---|
|
---|
20 μg/ml | 10 μg/ml | 5 μg/ml | 2.5 μg/ml | 1.25 μg/ml | 0.0 μg/ml |
---|
1:1000 | 0.427 | 0.417 | 0.416 | 0.414 | 0.399 | 0.075 |
1:2000 | 0.411 | 0.403 | 0.409 | 0.397 | 0.392 | 0.074 |
1:4000 | 0.386 | 0.391 | 0.381 | 0.373 | 0.37 | 0.071 |
1:8000 | 0.345 | 0.349 | 0.354 | 0.345 | 0.318 | 0.076 |
1:16000 | 0.279 | 0.295 | 0.31 | 0.299 | 0.262 | 0.073 |
1:32000 | 0.218 | 0.253 | 0.253 | 0.249 | 0.229 | 0.075 |
1:64000 | 0.173 | 0.198 | 0.21 | 0.203 | 0.175 | 0.078 |
0.0 | 0.075 | 0.071 | 0.079 | 0.076 | 0.071 | 0.074 |
Table 2:.
Selected competitive ELISA screening data against AcAaIT. AcAaIT polyhedrin was used as the coating antigen.
Table 2:.
Selected competitive ELISA screening data against AcAaIT. AcAaIT polyhedrin was used as the coating antigen.
Analytes | Coating antigen μg/ml | Antiserum dilution | IC50 μg/ml | Absorbance | Slope | Intercept |
---|
|
---|
min | max |
---|
AcAaIT | 2.5 | 1/4000 | 1.42 | 0.099 | 0.239 | 0.45 | 4.93 |
AcAaIT-field | 2.5 | 1/4000 | 122.93 | 0.195 | 0.296 | 0.37 | 4.23 |
AcMNPV | 2.5 | 1/4000 | 163.38 | 0.109 | 0.323 | 0.84 | 3.15 |
SlNPV | 2.5 | 1/4000 | 35.19 | 0.15 | 0.282 | 0.35 | 4.46 |
Table 3:.
Cross-reactivity of serum against AcAaIT polyhedrin
Table 3:.
Cross-reactivity of serum against AcAaIT polyhedrin
Origin of polyhedrin protein | Cross-reactivity* (%) |
---|
AcAaIT | 100 |
AcAaIT-field | 1.2 |
AcMNPV | 0.87 |
SlNPV | 4.0 |
Table 4:.
Leucocyte numbers following oral or intraperitoneal injection treatment of rats with SlNPV, AcMNPV or AcAaIT.
Table 4:.
Leucocyte numbers following oral or intraperitoneal injection treatment of rats with SlNPV, AcMNPV or AcAaIT.
Groups | Oral | Injection |
---|
|
---|
Male | Female | Male | Female |
---|
Control | 17.08±3.36* | 12.00±2.54 | 16.92±3.08 | 10.57±2.74 |
SlNPV | 15.17±2.47 (−11.2)** | 15.43±3.8 (+28.6) | 16.63±4.34 (−1.7) | 19.00±1.53 (+79.8) |
AcMNPV | 13.82±3.91 (−19.1) | 19.83±0.29 (+65.3) | 16.80±4.2 (−0.7) | 16.15±3.70 (+52.8) |
AcAaIT | 15.17±4.33 (−11.2) | 14.03±2.53 (+16.9) | 14.92±2.15 (−11.8) | 14.48±2.98 (+37.1) |
Table 5:.
Erythrocyte numbers following oral or intraperitoneal injection treatment of rats with SlNPV, AcMNPVor AcAaIT.
Table 5:.
Erythrocyte numbers following oral or intraperitoneal injection treatment of rats with SlNPV, AcMNPVor AcAaIT.
Groups | Oral | Injection |
---|
|
---|
Male | Female | Male | Female |
---|
Control | 7.9±0.5* | 10.5±0.9 | 7.8±1.7 | 9.6±1.3 |
SlNPV | 9.4±1.04 (+18.2)** | 10.8±1.2 (+2.4) | 9.2±1.4 (+18.4) | 7.2±1.4 (−7.3) |
AcMNPV | 8.5±1.1(+7.5) | 10.3±1.1 (−1.9) | 7.2±1.3 (−24.7) | 10.2±1.9 (+5.7) |
AcAaIT | 7.3±1.9 (−8.0) | 10.1±0.7 (−4.0) | 7.9±0.5 (+1.2) | 10.3±3.8 (+7.0) |
Table 6:.
Platelet numbers following oral or intraperitoneal injection treatment of rats with SlNPV, AcMNPV or AcAaIT.
Table 6:.
Platelet numbers following oral or intraperitoneal injection treatment of rats with SlNPV, AcMNPV or AcAaIT.
Groups | Oral | Injection |
---|
|
---|
Male | Female | Male | Female |
---|
Control | 261.3±16.2* | 310.7±64.3 | 280.7±70.5 | 263.7±41.7 |
SlNPV | 219.7±28.4 (−15.9)** | 281±45.4(−9.5) | 259±50.5 (−7.7) | 260±18.02 (−1.4) |
AcMNPV | 283.7±11.6 (+8.5) | 338.7±52.4 (+9.0) | 303±43.3 (+8.0) | 342±82.4 (+29.7) |
AcAaIT | 238±23.3 (−8.9) | 330±63.5 (+6.2) | 269.3±48.9 (−4.0) | 276±58.8 (+4.7) |
Table 7:.
Levels of total protein, glucose, and acetylcholinesterase in rat serum at 21 days after oral or intraperitoneal administration of SlNPV, AcMNPV or AcAaIT
Table 7:.
Levels of total protein, glucose, and acetylcholinesterase in rat serum at 21 days after oral or intraperitoneal administration of SlNPV, AcMNPV or AcAaIT
Group | Serum Level |
---|
|
---|
Oral | Injection |
---|
|
---|
Total protein (gm/dl) | Glucose (mg/dl) | Acetylcholinesterase (U/L) | Total protein (gm/dl) | Glucose (mg/dl) | Acetylcholinesterase (U/L) |
---|
Control | Male | 6.9 ± 0.6* | 133.8 ± 12.0 | 5.1 ± 0.9 | 9.5 ± 1.5 | 147.9 ± 20.6 | 6.0 ± 0.6*** |
Female | 8.7 ± 1.4 | 138.3 ± 18.8 | 6.7 ± 0.9 | 8.1 ± 0.3 | 180.1 ± 35.0 | 5.6 ± 0.8 |
|
SlNPV | Male | 7.8 ± 0.9 (+13.3)** | 128.6 ± 12.3 (−3.9) | 5.6 ± 0.9 (+10.5) | 8.2 ± 0.5 (−13.9) | 141.4 ± 37.0 (−4.4) | 6.2 ± 0.6 (+3.8) |
Female | 6.8 ± 0.1 (−21.7) | 188.9 ± 11.5 (+36.6) | 5.9 ± 1.0 (−12.5) | 8.2 ± 0.8 (+1.1) | 130.8 ± 8.7 (−27.3) | 5.9 ± 0.9 (+6.2) |
|
AcMNPV | Male | 7.0 ± 0.8 (+1.7) | 136.2 ± 4.8 (+1.8) | 5.3 ± 0.4 (+3.5) | 7.3 ± 1.0 (−23.5) | 141.5 ± 25.7 (−4.3) | 5.1 ± 0.5 (−15.2) |
Female | 7.9 ± 0.6 (−9.5) | 161.1 ± 33.4 (+16.4) | 5.1 ± 1.0 (−24.5) | 7.7 ± 0.4 (−4.2) | 163.7 ± 24.1 (−9.1) | 6.0 ± 0.9 (+7.6) |
|
AcAaIT | Male | 6.9 ± 0.4 (−0.4) | 155.1 ± 9.0 (+0.2) | 4.8 ± 0.9 (−4.9) | 6.4 ± 0.6 (−32.2) | 141.9 ± 22.9 (−4.1) | 5.6 ± 1.1 (−5.3) |
Female | 9.4 ± 1.04 (+8.2) | 82.7 ± 12.7 (−40.2) | 5.7 ± 0.7 (−14.7) | 8.7 ± 1.8 (+7.8) | 119.1 ± 12.8 (−33.9) | 5.0 ± 1.0 (−10.7) |
Table 8:.
Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin in rat serum at 21 days after oral or intraperitoneal administration of SlNPV, AcMNPV or AcAaIT
Table 8:.
Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin in rat serum at 21 days after oral or intraperitoneal administration of SlNPV, AcMNPV or AcAaIT
Groups | Serum Level |
---|
|
---|
Oral | Injection |
---|
|
---|
ALT (U/L) | AST (U/L) | ALP (U/L) | Bilirubin (mg/dl) | ALT (U/L) | AST (U/L) | ALP (U/L) | Bilirubin (mg/dl) |
---|
Control | Male | 12.2 ± 2.1* | 31.3 ± 1.3 | 105.4 ± 8.3 | 0.31 ± 0.06 | 10.0 ± 0.5 | 30.8 ± 1.8 72. | 7 ± 13.7 | 0.33 ± 0.07 |
Female | 8.0 ± 1.6 | 24.8 ± 3.3 | 81.8 ± 5.5 | 0.21 ± 0.04 | 8.8 ± 2.4 | 24.0 ± 1.3 | 76.4 ± 9.4 | 0.20 ± 0.03 |
|
SlNPV | Male | 10.0 ± 1.3 (−18.1)** | 25.8 ± 0.8 (−17.6) | 67.3 ± 8.3 (−36.2) | 0.34 ± 0.07 (+8.04) | 14.4 ± 1.7 (+44.0) | 25.3 ± 1.4 (−17.8) | 70.9 ± 10.9 (−2.5) | 0.38 ± 0.03 (+12.9) |
Female | 6.9 ± 0.6 (−13.3) | 18.7 ± 3.8 (−24.8) | 72.7 ± 13.7 (−11.1) | 0.28 ± 0.02 (+30.5) | 7.2 ± 1.9 (−18.9) | 19.8 ± 1.4 (−17.4) | 61.8 ± 8.3 (−19.0) | 0.36 ± 0.04 (+81.8) |
|
AcMNPV | Male | 10.1 ± 1.3 (−17.0) | 26.2 ± 1.04 (−16.5) | 87.3 ± 5.5 (−17.2) | 0.21 ± 0.04 (−34.5) | 10.9 ± 1.1 (+9.3) | 27.2 ± 2.8 (−11.9) | 58.2 ± 8.3 (−20.0) | 0.27 ± 0.05 (−18.3) |
Female | 6.7 ± 0.5 (−15.8) | 18.2 ± 1.5 (−26.8) | 74.5 ± 11.4 (−8.9) | 0.20 ± 0.04 (−1.7) | 6.5 ± 0.8 (−26.4) | 20.3 ± 2.8 (−15.3) | 69.1 ± 8.3 (−9.5) | 0.20 ± 0.03 (0.00) |
|
AcAaIT | Male | 8.1 ± 1.6 (−33.2) | 17.7 ± 0.8 (−43.6) | 78.2 ± 11.4 (−25.8) | 0.29 ± 0.03 (−8.04) | 8.6 ± 0.9 (−14.3) | 18.0 ± 1.0 (−41.6) | 65.4 ± 10.9 (−10.0) | 0.40 ± 0.04 (+19.4) |
Female | 7.4 ± 1.3 (−7.1) | 21.7 ± 3.7 (−12.8) | 83.6 ± 11.4 (+2.2) | 0.13 ± 0.01 (−37.3) | 13.8 ± 0.8 (+56.6) | 17.7 ± 3.8 (−26.4) | 70.9 ± 9.4 (−7.1) | 0.18 ± 0.01 (−7.3) |
Table 9:.
Levels creatinin and urea in rat serum at 21 days after oral or intraperitoneal administration of SlNPV, AcMNPV or AcAaIT
Table 9:.
Levels creatinin and urea in rat serum at 21 days after oral or intraperitoneal administration of SlNPV, AcMNPV or AcAaIT
Groups | Serum Level |
---|
|
---|
Oral | Injection |
---|
|
---|
Creatinin (mg/dl) | Urea (mg/dl) | Creatinin (mg/dl) | Urea (mg/dl) |
---|
Control | Male | 3.63 ± 0.41* | 43.7 ± 3.5 | 3.17 ± 0.13 | 43.0 ± 4.5 |
Female | 2.15 ± 0.07 | 39.1 ± 2.7 | 3.82 ± 0.13 | 45.9 ± 9.2 |
|
SlNPV | Male | 3.64 ± 0.31 (+0.4)** | 44.2 ± 2.2 (+1.1) | 3.36 ± 0.22 (+6.1) | 55.8 ± 4.8 (+30.0) |
Female | 3.04 ± 0.10 (+41.4) | 38.2 ± 7.3 (−2.2) | 2.94 ± 0.30 (−23.1) | 42.6 ± 3.0 (−7.2) |
|
AcMNPV | Male | 2.84 ± 0.03 (−21.6) | 48.3 ± 10.1 (+10.5) | 3.22 ± 0.01 (+1.5) | 45.7 ± 8.2 (+6.3) |
Female | 2.70 ± 0.11 (+25.7) | 43.5 ± 12.4 (+11.3) | 2.59 ± 0.12 (−32.2) | 46.4 ± 5.9 (+1.03) |
|
AcAaIT | Male | 2.53 ± 0.05 (−30.2) | 42.7 ± 5.0 (−2.2) | 3.09 ± 0.03 ( | 41.7 ± 4.3 (−2.9) |
Female | 3.07 ± 0.14 (+42.9) | 40.2 ± 8.9 (+2.8) | 2.61 ± 0.17 ( | 42.2 ± 2.6 (−8.1) |
Table 10:.
Phagocytic activity of head kidney cells from T. nilotica exposed to SlNPV, AcMNPV or AcAaIT.
Table 10:.
Phagocytic activity of head kidney cells from T. nilotica exposed to SlNPV, AcMNPV or AcAaIT.
Treatment | Phagocytic activity (mean ± S.D.) |
---|
|
---|
30 min | 60 min | 90 min | 120 min | 150 min | 180 min |
---|
Control | 73.3±5.8 | 78.3±7.6 | 86.7±7.6 | 93.3±1.5 | 93.3±1.5 | 94.3±2.5 |
SlNPV | 60.3±9.0 (−17.7)* | 71.0±5.3 (−9.3) | 80.7±5.1 (−6.9) | 84.0±7.9 (−9.9) | 86.7±5.8 (−7.1) | 88.7±7.8 (−5.9) |
AcMNPV | 59.0±3.6 (−19.5) | 67.0±6.1 (−14.4) | 75.0±5.0 (−13.5) | 83.3±5.8 (−10.7) | 92.3±3.1 (−1.1) | 92.7±3.5 (−1.7) |
AcAaIT | 55.3±5.0 (−24.6) | 66.7±5.8 (−14.8) | 80.7±7.0 (−6.9) | 88.0±4.4 (−5.7) | 90.3±0.6 (−3.2) | 93.0±1.7 (−1.4) |